AIDS and Behavior

, Volume 22, Issue 9, pp 2757–2765 | Cite as

Patterns of Substance Use and Arrest Histories Among Hospitalized HIV Drug Users: A Latent Class Analysis

  • Karen Shiu-YeeEmail author
  • Ahnalee M. Brincks
  • Daniel J. Feaster
  • Jemima A. Frimpong
  • Ank Nijhawan
  • Raul N. Mandler
  • Robert Schwartz
  • Carlos del Rio
  • Lisa R. Metsch
Original Paper


Using baseline data from the NIDA Clinical Trials Network 0049 study (Project HOPE), we performed latent class analyses (LCA) to identify discrete classes, or clusters, of people living with HIV (PLWH) based on their past year substance use behaviors and lifetime arrest history. We also performed multinomial logistic regressions to identify key characteristics associated with class membership. We identified 5 classes of substance users (minimal drug users, cocaine users, substantial cocaine/hazardous alcohol users, problem polysubstance users, substantial cocaine/heroin users) and 3 classes of arrest history (minimal arrests, non-drug arrests, drug-related arrests). While several demographic variables such as age and being Black or Hispanic were associated with class membership for some of the latent classes, participation in substance use treatment was the only covariate that was significantly associated with membership in all classes in both substance use and arrest history LCA models. Our analyses reveal complex patterns of behaviors among substance using PLWH and suggest that HIV intervention strategies may need to take into consideration such nuanced differences to better inform future studies and program implementation.


HIV/AIDS Substance abuse Arrest Criminal justice Latent class analysis 



The authors recognize the CTN-0049 staff for their dedication and we show gratitude to CTN-0049 collaborators, in particular the Public Health Trust/Jackson Health System, the Grady Health System, Johns Hopkins University, Boston Medical Center, Hahnemann University Hospital, Rush University Medical Center, Parkland Health and Human Services, University of Pittsburgh, University of California Los Angeles, University of Alabama at Birmingham, and Saint Luke’s Roosevelt Hospital, for their support on this project. CTN-0049 (Project HOPE) was funded by the NIH/NIDA National Drug Abuse Treatment Clinical Trials Network (U10-DA13720, PIs: Szapocznik, Metsch). Additionally, Ms. Shiu-Yee is supported by the NIH/NIDA HIV and Substance Abuse in the Criminal Justice System training program (T32-DA037801, PIs: El-Bassel, Metsch) and Dr. Frimpong is supported in-part by the NIH/NIDA Mentoring Early-Career Scientists for Drug Abuse Research Careers program (R25-DA035163, PIs: Masson, Sorensen). All authors contributed to the preparation of this manuscript. KS-Y, AMB, and DJF jointly conceived this analysis. AMB and DJF designed the LCA models and conducted the analysis with input from KS-Y. LRM was one of the principal investigators and she oversaw the design and data collection of Project HOPE.


CTN-0049 (Project HOPE) was funded by the NIH National Drug Abuse Treatment Clinical Trials Network (U10-DA13720).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

All study procedures involving human participants in CTN-0049 (Project HOPE) were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All procedures received IRB approval from study sites.

Informed Consent

Informed consent was obtained from all participants included in the study.


  1. 1.
    Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Palepu A, Tyndall MW, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JSG. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32:522–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individual in the United States and Canada. PLoS ONE. 2013;8(12):e81355.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kipp AM, Rebeiro PF, Shepherd BE, et al. Daily marijuana use is associated with missed clinic appointments among HIV-infected persons engaged in HIV care. AIDS Behav. 2017;[ePub ahead of print].Google Scholar
  6. 6.
    Qian H-Z, Mitchell VJ, Bebawy S, et al. Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. BMC Infect Dis. 2014;14:508.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Viswanathan S, Detels R, Mehta SH, Macatangay BJC, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Howe CJ, Cole SR, Napravnik S, et al. The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV+ African Americans. AIDS Res Hum Retrovir. 2014;30(3):233–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163(5):412–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58.CrossRefPubMedGoogle Scholar
  12. 12.
    Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15.CrossRefPubMedGoogle Scholar
  13. 13.
    Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Schoenbaum EE, Lo Y, Floris-Moore M. Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000. Public Health Rep. 2002;117(Suppl 1):S60–6.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Federal Bureau of Prisons. Inmate Statistics—Offenses. Accessed 30 Sept 2017.
  18. 18.
    Carson EA. Prisoners in 2015. Accessed 27 Apr 2017.
  19. 19.
    Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53:725–31.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rozanova J, Brown S-E, Bhushan A, Marcus R, Altice FL. Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. Health Justice. 2015;3:18.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kranofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191–205.Google Scholar
  23. 23.
    Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test: guidelines for use in primary care. 2nd ed. 2001.Google Scholar
  24. 24.
    Skinner HA. The drug abuse screening test. Addict Behav. 1982;7(4):363–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Derogatis LR, Fitzpatrick M. The SCL-90-R, the brief symptom inventory (BSI), and the BSI-18. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment: instruments for adults, vol 3. 3rd ed. Mahwah: Lawrence Erlbaum Associates Publishers; 2004. p. 1–41.Google Scholar
  26. 26.
    Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Model. 2007;14(4):671–94.CrossRefGoogle Scholar
  27. 27.
    Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535–69.CrossRefGoogle Scholar
  28. 28.
    Mplus Version 7.0 [computer program]. Version 7th. Los Angeles, California: Muthén & Muthén; 2012.Google Scholar
  29. 29.
    Stata Statistical Software. Release 12 [computer program]. College Station: StataCorp LP; 2011.Google Scholar
  30. 30.
    Bandeen-Roche K, Miglioretti DL, Zeger SL, Rathouz PJ. Latent variable regression for multiple discrete outcomes. J Am Stat Assoc. 1997;92(440):1375–86.CrossRefGoogle Scholar
  31. 31.
    Wang C-P, Hendricks Brown C, Bandeen-Roche K. Residual diagnostics for growth mixture models. J Am Stat Assoc. 2005;100(471):1054–76.CrossRefGoogle Scholar
  32. 32.
    Rubin DD. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.CrossRefGoogle Scholar
  33. 33.
    Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188–94.CrossRefPubMedGoogle Scholar
  35. 35.
    Korthuis PT, Fiellin DA, McGinnis KA, et al. Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr. 2012;61(2):171–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Reilly KH, Neaigus A, Wendel T, Marshall DM IV, Hagan H. Bisexual behavior among male injection drug users in New York City. AIDS Behav. 2016;20(2):405–16.CrossRefPubMedGoogle Scholar
  37. 37.
    CDC. HIV Surveillance Report, 2015; vol. 27. 2016; Accessed 23 Mar 2017.
  38. 38.
    Lurigio AJ. The first 20 years of drug treatment courts: a brief description of their history and impact. Fed Probat. 2008;72(1):13–7.Google Scholar
  39. 39.
    Tross S, Campbell AN, Cohen LR, et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of a NIDA Clinical Trials Network trial. J Acquir Immune Defic Syndr. 2008;48(5):581–9.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Alemi F, Taxman F, Baghi H, Vang J, Thanner M, Doyon V. Costs and benefits of combining probation and substance abuse treatment. J Ment Health Policy Econ. 2006;9(2):57–70.PubMedGoogle Scholar
  42. 42.
    Abraham AJ, O’Brien LA, Knudsen HK, Bride BE, Smith GR, Roman PM. Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder (SUD) treatment programs. J Subst Abuse Treat. 2014;44(1):120–5.CrossRefGoogle Scholar
  43. 43.
    Aletaris L, Roman PM. Provision of onsite HIV services in substance use disorder treatment programs: a longitudinal analysis. J Subst Abuse Treat. 2015;57:1–8.CrossRefGoogle Scholar
  44. 44.
    Feletcher BW, Lehman WEK, Wexler HK, Melnick G, Taxman FS, Young DW. Measuring collaboration and integration activities in criminal justice and substance abuse treatment agencies. Drug Alcohol Depend. 2009;103(Supplement 1):S54–64.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Karen Shiu-Yee
    • 1
    Email author
  • Ahnalee M. Brincks
    • 2
  • Daniel J. Feaster
    • 3
  • Jemima A. Frimpong
    • 4
  • Ank Nijhawan
    • 5
  • Raul N. Mandler
    • 6
  • Robert Schwartz
    • 7
  • Carlos del Rio
    • 8
  • Lisa R. Metsch
    • 1
  1. 1.Department of Sociomedical SciencesMailman School of Public HealthNew YorkUSA
  2. 2.Department of Epidemiology and BiostatisticsMichigan State UniversityEast LansingUSA
  3. 3.Division of BiostatisticsUniversity of Miami Miller School of MedicineMiamiUSA
  4. 4.The Johns Hopkins Carey Business SchoolBaltimoreUSA
  5. 5.Division of Infectious DiseasesUT Southwestern Medical CenterDallasUSA
  6. 6.National Institute on Drug AbuseRockvilleUSA
  7. 7.Friends Research InstituteBaltimoreUSA
  8. 8.Department of Global HealthRollins School of Public HealthAtlantaUSA

Personalised recommendations